Table 2.
Treatment with heart failure medications of prognostic relevance at baseline and 12 month follow‐up
| Class of drug | Baseline, n (%) | % target dose | 12 months, n (%) | % target dose |
|---|---|---|---|---|
| Beta‐blocker (n) | 29 (97) | 61 | 18 (86) | 64 |
| ACEi or ARB (n) | 13 (43) | 61 | 6 (29) | 58 |
| ARNI (n) | 15 (50) | 67 | 15 (71) | 63 |
| MRA (n) | 19 (63) | 54 | 13 (62) | 50 |
| SGLT2i (n) | 5 (17) | n.a. | 9 (43) | n.a. |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium–glucose cotransporter 2 inhibitor.
Data were obtained in 30 patients at baseline and 21 patients at follow‐up.